Pires I, Ni K, Melo M, Li N, Ben-Akiva E, Maiorino L
Chem Eng J. 2024; 464.
PMID: 38737525
PMC: 11081102.
DOI: 10.1016/j.cej.2023.142664.
Friedman-Klabanoff D, Berry A, Travassos M, Shriver M, Cox C, Butts J
J Infect Dis. 2024; 229(6):1883-1893.
PMID: 38330357
PMC: 11175675.
DOI: 10.1093/infdis/jiae062.
Chen K, Wang N, Zhang X, Wang M, Liu Y, Shi Y
Front Immunol. 2023; 14:1153042.
PMID: 37020548
PMC: 10067588.
DOI: 10.3389/fimmu.2023.1153042.
Friedman-Klabanoff D, Berry A, Travassos M, Cox C, Zhou Y, Mo A
Vaccine. 2021; 39(8):1195-1200.
PMID: 33494963
PMC: 9014455.
DOI: 10.1016/j.vaccine.2020.12.023.
Da Silva D, Skeate J, Chavez-Juan E, Luhen K, Wu J, Wu C
Vaccine. 2019; 37(22):2915-2924.
PMID: 31010714
PMC: 6586561.
DOI: 10.1016/j.vaccine.2019.04.043.
Quillaja saponaria bark saponin protects Wistar rats against ferrous sulphate-induced oxidative and inflammatory liver damage.
Abdel-Reheim M, Messiha B, Abo-Saif A
Pharm Biol. 2017; 55(1):1972-1983.
PMID: 28728456
PMC: 6130630.
DOI: 10.1080/13880209.2017.1345950.
Lysosome-Dependent Activation of Human Dendritic Cells by the Vaccine Adjuvant QS-21.
Welsby I, Detienne S, NKuli F, Thomas S, Wouters S, Bechtold V
Front Immunol. 2017; 7:663.
PMID: 28105029
PMC: 5215313.
DOI: 10.3389/fimmu.2016.00663.
Immunization Against Cutaneous Leishmaniasis by Alginate Microspheres Loaded With Autoclaved Leishmania Major (ALM) and Quillaja Saponins.
Tafaghodi M, Eskandari M, Khamesipour A, Jaafari M
Iran J Pharm Res. 2016; 15(2):573-81.
PMID: 27642328
PMC: 5018285.
Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines.
Bobbala S, Tamboli V, McDowell A, Mitra A, Hook S
AAPS J. 2015; 18(1):261-9.
PMID: 26589309
PMC: 4706273.
DOI: 10.1208/s12248-015-9843-4.
Recent progress in adjuvant discovery for peptide-based subunit vaccines.
Azmi F, Ahmad Fuaad A, Skwarczynski M, Toth I
Hum Vaccin Immunother. 2013; 10(3):778-96.
PMID: 24300669
PMC: 4130256.
DOI: 10.4161/hv.27332.
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.
Sivakumar S, Safhi M, Kannadasan M, Sukumaran N
Saudi Pharm J. 2013; 19(4):197-206.
PMID: 23960760
PMC: 3744968.
DOI: 10.1016/j.jsps.2011.06.003.
A review of adjuvants for Leishmania vaccine candidates.
Mutiso J, Macharia J, Gicheru M
J Biomed Res. 2013; 24(1):16-25.
PMID: 23554607
PMC: 3596531.
DOI: 10.1016/S1674-8301(10)60004-8.
Pre-erythrocytic malaria vaccines: identifying the targets.
Duffy P, Sahu T, Akue A, Milman N, Anderson C
Expert Rev Vaccines. 2012; 11(10):1261-80.
PMID: 23176657
PMC: 3584156.
DOI: 10.1586/erv.12.92.
Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice.
Wen Z, Xu Y, Zou X, Xu Z
Mar Drugs. 2011; 9(6):1038-1055.
PMID: 21747747
PMC: 3131560.
DOI: 10.3390/md9061038.
Carbohydrate-based immune adjuvants.
Petrovsky N, Cooper P
Expert Rev Vaccines. 2011; 10(4):523-37.
PMID: 21506649
PMC: 3118391.
DOI: 10.1586/erv.11.30.
Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.
Boutajangout A, Goni F, Knudsen E, Schreiber F, Asuni A, Quartermain D
J Alzheimers Dis. 2009; 18(4):961-72.
PMID: 19749432
PMC: 2842483.
DOI: 10.3233/JAD-2009-1204.
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
Sigurdsson E
J Alzheimers Dis. 2008; 15(2):157-68.
PMID: 18953105
PMC: 2757121.
DOI: 10.3233/jad-2008-15202.
Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.
Hui G, Hashimoto C
Int Immunopharmacol. 2008; 8(7):1012-22.
PMID: 18486913
PMC: 2464358.
DOI: 10.1016/j.intimp.2008.03.005.
The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
Hui G, Hashimoto C
Vaccine. 2007; 25(51):8549-56.
PMID: 18006124
PMC: 2211737.
DOI: 10.1016/j.vaccine.2007.10.010.
Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
Hui G, Hashimoto C
Vaccine. 2007; 25(36):6598-603.
PMID: 17688975
PMC: 2259241.
DOI: 10.1016/j.vaccine.2007.06.057.
